Weight loss drugs are changing the economic picture from many angles. In addition to reshaping the healthcare, retail, and leisure industries, employers—including Bank of America—are now offering access to the medication as part of their healthcare benefits. In fact, the impact of GLP-1s has become so huge that it is influencing the forecast for the entire Danish economy, which is home to pharmaceutical giant Novo Nordisk: the company behind Ozempic and Wegovy. In a special report, the Danmarks Nationalbank (Denmark's central bank), noted the country's pharmaceutical industry saw "extraordinary" growth in the first half of 2026, with an increasing share of production taking place abroad under Danish ownership.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.